Ginkgo Bioworks Holdings (DNA) EBITDA Margin (2020 - 2026)
Ginkgo Bioworks Holdings posted quarterly EBITDA Margin of 427.46% for Q1 2026, down 19204.0% year-on-year from N/an in Q1 2025, and down 76.47% on a QoQ basis from 242.23% in Q4 2025.
Ginkgo Bioworks Holdings (DNA) has 7 years of EBITDA Margin data on file, last reported at 427.46% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 19204.0% year-over-year to 427.46%; the trailing twelve-month figure through Mar 2026 stood at 213.96% (down 661.0% YoY), and the FY2025 full-year result was 181.66%, up 6072.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 427.46%, down from 242.23% in the prior quarter.
- Across five years, EBITDA Margin topped out at 61.11% in Q3 2024 and bottomed at 1012.9% in Q3 2022.
- The 5-year median for EBITDA Margin is 252.72% (2023), against an average of 353.97%.
- Peak annual rise in EBITDA Margin reached 96382 bps in 2022, while the deepest fall reached 97853 bps in 2022.
- A 5-year view of EBITDA Margin shows it stood at 170.73% in 2022, then sank by 249 bps to 596.49% in 2023, then soared by 58 bps to 249.97% in 2024, then advanced by 3 bps to 242.23% in 2025, then plunged by 76 bps to 427.46% in 2026.
- The last three EBITDA Margin figures came in at 427.46% (Q1 2026), 242.23% (Q4 2025), and 207.05% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn | -427.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -427.46% |
| Dec 31, 2025 | -242.23% |
| Sep 30, 2025 | -207.05% |
| Jun 30, 2025 | -116.52% |
| Mar 31, 2025 | -235.42% |
| Dec 31, 2024 | -249.97% |
| Sep 30, 2024 | -61.11% |
| Jun 30, 2024 | -386.71% |
| Mar 31, 2024 | -445.25% |
| Dec 31, 2023 | -596.49% |
| Sep 30, 2023 | -549.32% |
| Jun 30, 2023 | -214.73% |
| Mar 31, 2023 | -252.72% |
| Dec 31, 2022 | -170.73% |
| Sep 30, 2022 | -1,012.90% |
| Jun 30, 2022 | -447.92% |
| Mar 31, 2022 | -401.04% |
| Dec 31, 2021 | -1,134.55% |
| Sep 30, 2021 | -34.37% |
| Jun 30, 2021 | -137.38% |
| Mar 31, 2021 | -129.52% |
| Dec 31, 2020 | -174.33% |
| Sep 30, 2020 | -258.71% |